| 000 | 01475 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250517081357.0 | ||
| 264 | 0 | _c20160728 | |
| 008 | 201607s 0 0 eng d | ||
| 022 | _a1879-0631 | ||
| 024 | 7 |
_a10.1016/j.lfs.2016.02.042 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJadhav, Vaibhav | |
| 245 | 0 | 0 |
_aBiocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines. _h[electronic resource] |
| 260 |
_bLife sciences _cMar 2016 |
||
| 300 |
_a41-52 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aArsenic Trioxide |
| 650 | 0 | 4 |
_aArsenicals _xpharmacology |
| 650 | 0 | 4 |
_aBiocompatible Materials _xpharmacology |
| 650 | 0 | 4 |
_aCell Cycle Checkpoints _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase Inhibitor p21 _xbiosynthesis |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEpigenesis, Genetic _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetal Nanoparticles _xtherapeutic use |
| 650 | 0 | 4 |
_aOxides _xpharmacology |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 700 | 1 | _aRay, Pritha | |
| 700 | 1 | _aSachdeva, Geetanjali | |
| 700 | 1 | _aBhatt, Purvi | |
| 773 | 0 |
_tLife sciences _gvol. 148 _gp. 41-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.lfs.2016.02.042 _zAvailable from publisher's website |
| 999 |
_c25739631 _d25739631 |
||